Apeiron strikes again


Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by stimulating the immune system. The transaction follows in the wake of other successful in-licensing deals that Apeiron has completed in the last six months. The collaboration includes an option for Apeiron to enter into a worldwide, exclusive licensing agreement with the Cleveland Clinic relating to the compounds, and a research agreement sponsored by Apeiron relating to these compounds and approach. The approach involves tyrosine phosphatase inhibitors (TPI) inhibiting SHP-1, a protein tyrosine phosphatase that is a key negative regulator of immune cell activation. Inhibition of SHP-1 leads to activation of the immune system to combat cancer. Apeiron CEO Hans Loibner called the deal a “great collaboration for Apeiron,“ adding that he regards the compounds developed at the Cleveland Clinic as “an attractive opportunity, since they are designed to activate the patient’s own immune system.” Loibner has been a specialist for immune therapies in oncology for more than twenty years. Apeiron will also close a financing round to fund the development of its clinical pipeline.



Vienna – Austria-based Intercell AG yesterday announced that its first-in-man trial of the subunit vaccine IV47, designed to prevent infections from the majority of so Streptococcus pneumoniae serotypes, of which there are over...



Vienna – Austrian-based biotech company f-star has closed an EUR8m extension to its Series A financing round. The investment was co-led by MP Healthcare Venture Management and Merck Serono Ventures. Existing investors Atlas...



Vienna – With the naming of Beatrix Karl as the new Minister of Science, the Austrian government is complete. The 42 year-old legal scientist will follow pre­decessor Johannes Hahn, who has accepted a position as European...





Vienna – Austrian vaccine specialist Intercell and GlaxoSmithKline Biologicals SA (GSK) have formed a strategic alliance to commercialise needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine...



Vienna – Austrian firm Intercell AG has initiated a phase II efficacy trial as part of its clinical development program for the investigational travellers’ diarrhoea (TD) vaccine in India. The primary objective of the field trial...



Vienna – Austrian vaccine specialist Intercell AG is to expand the label of its vaccine Ixiaro/JEspect for Japanese encephalitis (JE). On Monday the company announced the start of a clinical phase III study for the travel...

Politics / Law, Miscellaneous, AustriaAustria


Graz – Austria is likely to lead the EU’s efforts to integrate existing national biobanks and associated data throughout Europe into a European biobanking infrastructure. The resource is aimed at reaching critical mass for the...



Vienna – Cardiovascular and inflammatory specialist Fibrex Medical has published positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – damage to heart muscle that results from remedial treatment...

Politics / Law, AustriaAustria


The cultivation of genetically modified organisms (GMOs) in the European Union could soon no longer be decided by scientific facts, but by political preferences. Fourteen member states – among them France, Poland and Portugal –...

Displaying results 31 to 40 out of 116

< Previous 31-40 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%


  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015

Current issue

All issues